A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at ...

A new risk score can help predict which pancreatic cancer survivors are more likely to suffer a recurrence of their cancer, ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

An AI model significantly improved recurrence risk stratification vs. recurrence score among patients with hormone ...

Ahmedabad-based Zydus Lifesciences Ltd has inked a pact with precision diagnostics company Myriad Genetics from the USA to ...

The MarketWatch News Department was not involved in the creation of this content. New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger ...

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Yes, my wife went there. Someone I’d known for more than half my life, someone I covered during my days as a sportswriter had died. Of prostate cancer. The same disease I was diagnosed with in July.